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a  b  s  t  r  a  c  t
Objective: To analyze the frequencies of the expression of major histocompatibility complex
class I (MHC-I) antigens, and CD4 and CD8 cells in skeletal muscle in polymyositis (PM) and
dermatomyositis (DM).
Methods: This was a retrospective study of 34 PM cases, 8 DM cases, and 29 control patients
with  non-inﬂammatory myopathies.
Results: MHC-I antigens were expressed in the sarcolemma and/or sarcoplasm in 79.4% of PM
cases, 62.5% of DM cases, and 27.6% of controls (CD4 expression was observed in 76.5%, 75%,
and  13.8%, respectively). There was a high suspicion of PM/DM (mainly PM)  in participants
in  whom MHC-I antigens and CD4 were co-expressed. In 14.3% of PM/DM cases, we  observed
MHC-I antigens expression alone, without inﬂammatory cells.
Conclusion: MHC-I antigens expression and CD4 positivity might add to strong diagnostic
suspicion of PM/DM. No cellular inﬁltration was observed in approximately 14.3% of such
cases.
©  2014 Elsevier Editora Ltda. All rights reserved.
Expressão  de  antígenos  MHC  classe  I  e  de  células  CD4  e  CD8  na
polimiosite  e  dermatomiosite
alavras-chave:
atologia muscular
muno-histoquímica muscular
r  e  s  u  m  o
Objetivo: Analisar as frequências de expressão dos antígenos de complexo principal de histo-
compatibilidade classe I (MHC-I)  e células CD4 e CD8 no músculo esquelético na polimiosite
(PM) e dermatomiosite (DM).
iópsia muscular
ntígenos de complexo principal de
Métodos: Estudo retrospectivo de 34 casos de PM, 8 casos de DM e 29 controles com miopatias
não  inﬂamatórias.
istocompatibilidade classe I
MHC-I)
iopatias inﬂamatórias
Resultados: Os antígenos MHC-I expressaram-se no sarcolema e/ou sarcoplasma em 79,4%
dos  casos de PM, 62,5% dos casos de DM e 27,6% dos controles (a expressão de CD4 foi
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observada em 76,5%, 75% e 13,8%, respectivamente). Quando os antígenos MHC-I foram
coexpressados com CD4, houve elevada suspeita de PM/DM (principalmente PM). Em 14,3%
dos  casos de PM/DM, observou-se a expressão isolada dos antígenos MHC-I, sem células
inﬂamatórias.
Conclusão: A expressão dos antígenos MHC-I e a positividade do CD4 podem aumentar a
suspeita diagnóstica de PM/DM. Não foi observado inﬁltrado celular em 14,3% dos casos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Inﬂammatory myopathies (IM) constitute a heterogeneous
group of autoimmune diseases that are characterized clin-
ically by weakness and inﬂammation in skeletal muscle.
Accurate diagnosis is critical, as IM are potentially treat-
able myopathies. Based on clinical and histopathological
characteristics, three main subgroups of IM were deﬁned:
polymyositis (PM), dermatomyositis (DM), and inclusion body
myositis (IBM). The diagnosis of these diseases is based on
clinical examination and laboratory tests, particularly crea-
tine kinase, electromyogram, and muscle pathology ﬁndings
obtained after biopsy.1–3 The hallmarks for correct diagnosis
on muscle biopsy are muscle ﬁber necrosis (usually in iso-
lated spots) and the presence of inﬂammatory cells in the
perimysial and endomysial regions, and also often in perivas-
cular regions. A typical ﬁnding is lymphocytic non-necrotic
ﬁber invasion, which is soon replaced by macrophages and
T-cells after it becomes necrotic.4 Perifascicular atrophy is spe-
ciﬁc to and a hallmark feature of DM,  as rimmed-vacuoles
are for IBM.4 It is well recognized that the absence of inﬂam-
matory inﬁltrates does not exclude an IM.  In these cases, the
presence of major histocompatibility complex class I (MHC-I)
antigens in sarcolemma and/or sarcoplasm might contribute
to diagnostic suspicion of IM,  although it is not speciﬁc to
IM.
In normal muscle ﬁbers, MHC-I antigens are only detected
on blood vessels and can be easily seen on endomysial
capillaries. In contrast, in IM MHC-I antigens expression were
observed on the sarcolemma and also internally (sarcoplasm)
in several ﬁbers.5,6 MHC-I antigens induction and expression
occurs early, frequently before the inﬂammatory inﬁltrates,
and continues throughout the evolution of this chronic dis-
ease, even with the use of immunosuppression and after
apparent clinical remission.1,7–10
Regenerating and/or immature muscle ﬁbers exhibited
consistent MHC  I antigens sarcolemmal expression irre-
spective of disease;11 because of that, it is important to
distinguish this normal ﬁnding from the abnormal labeling
on mature ﬁbers by using a marker for immaturity, such
as neonatal myosin.4 The expression of MHC-I in the sar-
colemma and/or the sarcoplasm of mature muscle ﬁbers is
abnormal and represents a useful tool for the diagnosis of
IM,  particularly in the absence of inﬂammatory inﬁltrates,
muscle ﬁber necrosis, rimmed vacuoles, or perifascicular atro-
phy.The present study was ﬁgured out to emphasize the
importance of routinely making the MHC I antigens
together with subtypes of T cells expression on musclebiopsy techniques if there is IM suspicion. In spite of
the IM pathological hallmark ﬁnding being an inﬂamma-
tory inﬁltrate (as stressed above), sometimes this could be
missed.
Material  and  methods
Patients
Seventy-one patients assisted at the Hospital de Base,
Faculdade de Medicina de São José do Rio Preto
(FAMERP) were studied, from June 2005 to June 2013.
They were referred for muscle biopsy from several
medical specialties, particularly neurology and rheuma-
tology.
Two patient groups were constituted for evaluation. Group
1 consisted of 42 patients with a consistent clinical pic-
ture and muscle pathology characteristic of PM or DM,  as
follows: muscle necrosis, endomysial and/or perivascular
inﬂammatory inﬁltrate (Fig. 1A and B), invasion of non-
necrotic muscle ﬁbers, and/or perifascicular atrophy. Group
2 consisted of 29 patients referred for muscle biopsy with
suspicion of a myopathy other than IM, but with normal or
non-speciﬁc and non-inﬂammatory muscle pathology abnor-
malities.
Muscle  biopsy
All muscle biopsies from Deltoideus were performed by a
physician specialized in neuromuscular disorders, using an
open technique under local anesthesia. Each muscle sample
was forwarded to the Laboratory of Neuromuscular Investi-
gation in a fresh state with no ﬁxatives or additives, and
was immediately frozen in liquid nitrogen and stored at
−176 ◦C until processing. Frozen muscle specimens were
cut into sections of 5 m thickness using a cryostat at a
temperature of −30 ◦C, and slices were mounted on glass
slides coated in poly-lysine. The distribution of MHC-I anti-
gens was investigated using a monoclonal antibody by the
immunoperoxidase technique. Antibodies labeling to be seen
under optical microscopy were performed using a polymer
detection system (NovoLink Max Polymer Detection System,
Novocastra Laboratories Ltd., Newcastle upon-Tyne, England)
according to the manufacturer’s instructions. The antibod-
ies used were: anti-MHC-I (Rhea Biotech, Campinas, Brazil),
anti-CD8 (monoclonal mouse, 1A5 clone, IgG1 isotype), and
anti-CD4 (monoclonal mouse, 4B12 clone, IgG1 isotype). CD4
and CD8 antibodies were from DakoCytomation Denmark A/S,
Denmark.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(3):203–208 205
Fig. 1 – Deltoideus muscle biopsy from a patient with inﬂammatory myopathy. (A) Muscle ﬁber necrosis and endomysial
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tatistics
 Chi-squared test was used for the comparison of two propor-
ions, expressed as a percentage. p-values <0.05 were deﬁned
s statistically signiﬁcant.
thics
he study was approved by the ethics committee of the
AMERP.
esults
roup 1 encompassed of 42 patients (PM or DM): 28 female
66.7%) and 14 male (33.3%), mean age 44.7 ± 19.9 years
range 6–80 years). Thirty-four of these 42 cases (80.1%) were
M patients [22 female (64.7%) and 12 male (35.3%); mean
ge 49.3 ± 17.7 years (range 8–80 years)]. The remaining 8
ases (19.9%) were DM patients [6 female (75%) and 2 male
25%); mean age 25.3 ± 17.4 years (range 6–51 years)]. Group 2
onsisted of 29 patients: 17 female (58.6%) and 12 male (41.4%),
ean age 34.2 ± 21.9 years (range 1–71 years).
The frequency of MHC-I antigens expression in muscle
bers are shown in detail in table. Fig. 2A–C depicts its expres-
ion in the sarcolemma or sarcoplasm, as well as lack of
xpression. MHC-I antigens expression in either sarcoplasm
r sarcolemma were observed in 79.4% of PM patients, 62.5%
f DM patients, and 27.6% of controls. No MHC-I antigens
xpression were observed in either the sarcolemma or the sar-
oplasm in 20.6% of PM patients, 37.5% of DM patients, and
2.4% of controls.
The frequencies of antibody positivity for CD4 and CD8
re detailed in Table 1. Fig. 3A–C depicts CD4/CD8 expression
ainly in the endomysium. The majority of PM cases (76.5%)
ested positive for CD4 expression, while 23.5% tested negative
or both CD4 and CD8. Similarly, 75% of DM cases tested pos-
tive for CD4, and 25% tested negative for both CD4 and CD8.
ither CD4 or CD8 expression was observed in 24.1% of con-
rol samples; however, expression of both CD4 and CD8 was
bserved in 0% of control samples, and 75.9% tested negative
or both CD4 and CD8.osomal activity (acid phosphatase).
MHC-I antigens expression in either the sarcoplasm or the
sarcolemma were observed together with CD4 positivity in
88.2% of PM, 50% of DM, and 3.5% of control samples. In com-
parison, MHC-I antigens expression in either the sarcoplasm
or the sarcolemma were observed together with CD8 positivity
in 35.3% of PM, 12.5% of DM, and 0% of control samples.
In 5 PM cases (14.7%) and in 1 DM case (12.5%), MHC-I anti-
gens were expressed either in sarcolemma or sarcoplasm in
the absence of both CD4 and CD8.
Discussion
The present study demonstrated that the expression of MHC-I
antigens in either the sarcolemma or the sarcoplasm occurred
more  often in patients with PM/DM than in controls, although
only the difference between controls and PM patients was sta-
tistically signiﬁcant. Overall, MHC-I antigens were expressed
in 79.4% of PM/DM patients. Overall, the sensitivity of the test
for diagnosing IM was 78%, similar to ours (79.4%).12 When
we considered only sarcolemmal MHC-I antigens expression,
there was no signiﬁcant difference between controls and
either PM or DM patients. When we  considered only sarcoplas-
mic  MHC-I antigens expression, the difference was signiﬁcant
only between controls versus PM patients. MHC-I antigens
were not expressed in both sarcolemma and sarcoplasm in
most controls, which differed signiﬁcantly only from PM cases.
According Karpati et al.,11 in PM the majority of muscle ﬁbers
exhibited strong sarcolemmal MHC-I antigens expression and
in DM, muscle ﬁbers situated perifascicularly or distributed in
random clusters revealed strong expression.
Overall, 76.2% of PM/DM patients tested positive for CD4
and/or CD8. The positivity of inﬂammatory cells (CD4) was
higher in cases with PM/DM versus controls, with a signiﬁcant
difference for both. CD8 positivity was less pronounced but
still signiﬁcant for PM cases, although not for DM cases. The
rate at which controls tested negative for CD4  and CD8  was sig-
niﬁcant when compared with both PM and DM.  None on the
controls were positive for both CD4 and CD8 and represented
a striking ﬁnding.
The expression of MHC-I antigens in either the sarcolemma
or the sarcoplasm in combination with CD4 positivity were
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 negFig. 2 – MHC-I antigens expression in muscle ﬁbers. (A)
the most common ﬁnding in PM versus controls, and this was
the most useful ﬁnding for PM diagnosis. This ﬁnding was less
useful for DM diagnosis, although it was still a useful ﬁnding in
that context. It is also worthwhile to emphasize that we did not
observe any association between MHC-I antigens expression
(either in sarcolemma or sarcoplasm) and CD8 expression in
control samples. This ﬁnding likely represents a very useful
tool to rule out PM/DM.
We observed no inﬂammatory inﬁltrate in 5 PM and 1 DM
cases, although MHC-I antigens were expressed either in the
sarcolemma or in the sarcoplasm. This ﬁnding showed that
approximately 15% of PM/DM cases could not be diagnosed
based only on inﬂammatory inﬁltrate, corroborating the state-
ment from Dalakas1 that the expression of MHC-I antigens are
a useful marker to conﬁrm the diagnosis of IM even when there
is no evidence of inﬂammatory cells in the muscle biopsy.
According to muscle biopsy results from van der Pas
et al.,13 the expression of MHC-I antigens were observed in
67% patients with DM and in 61% of patients with PM. In
DM cases, the immunohistochemical analysis revealed sig-
niﬁcantly higher MHC-I antigens expression in the juvenile
form (96.4%) than in the adult form (50%).12 MHC-I antigens
Table 1 – Expression of MHC-I antigens (sarcolemma and sarco
with polymyositis (PM), dermatomyositis (DM) and controls (C).
PM DM 
N 34 8 
Age 49.3 ± 19.9 25.3 ± 17
Male 35.3% (12) 25% (2) 
Female 64.7% (22) 75% (6) 
MHC-I (+) sarcolemma 47.1% (25) 62.5% (5
MHC-I (+) sarcoplasma 73.5% (16) 50.0% (4
MHC-I (+) both 41.2% (14) 50.0% (4
MHC-I (+) (either) 79.4% (27) 62.5% (5
MHC-I (−) both 20.6% (7) 37.5% (3
CD8 (+) 38.2% (13) 12.5% (1
CD4 (+) 76.5% (26) 75.0% (6
CD4 and CD8 (+) 38.2% (13) 12.5% (1
CD4 and/or CD8 (+) 76.5% (26) 75.0% (6
CD4 and CD8 (−) 23.5% (8) 25.0% (2
MHC-I (either) and CD4 (+) 88.2% (30) 50.0% (4
MHC-I (either) and CD8 (+) 35.3% (12) 12.5% (1
p < 0.05 was considered statistically signiﬁcant.ative; (B) sarcolemma; (C) sarcolemma and sarcoplasm.
expression were observed in 11% of biopsies from patients
with muscular dystrophy and in 4% of biopsies from patients
with a miscellaneous neuromuscular disorder, totaling 15%
(less than our observed expression of 27.6%).
Most muscle ﬁbers invaded by CD4 and/or CD8  express
MHC-I antigens on the surface.7 However, as noted above,
sometimes the MHC-I antigens expression were observed
without invasion by mononuclear cells. Nyberg et al.14 has also
emphasized the importance of MHC-I antigens expression in
inactive chronic PM or DM with persistent muscle weakness
in the absence of both inﬂammatory inﬁltrates and signs of
inﬂammation on magnetic resonance imaging. In addition,
the expression of MHC-I antigens are not modiﬁed by prior
treatment with immunosuppressive drugs, although van der
Pas et al.13 reported a decrease of sensitivity for the MHC-I
antigens test after 4 weeks of immunosuppressive therapy.
It should be emphasized that MHC-I antigens can also
be expressed in muscular dystrophies (mainly dysferlin
deﬁciency, which clinically presents as limb-girdle dystro-
phy and distal myopathy).15 In these cases, an increased
inﬂammatory response was observed together with an active
dystrophic pattern. The cellular inﬁltrates suggest that the
plasm), CD4 and CD8 in muscle biopsies from patients
Controls p p
29 PM/C DM/C
.4 34.2 ± 21.9
41.4% (12)
58.6% (17)
) 24.1% (7) 0.1037 0.1035
) 13.8% (4) <0.0001 0.0860
) 10.3% (3) 0.0135 0.0424
) 27.6% (8) 0.0001 0.1579
) 72.4% (21) 0.0001 0.1579
) 10.3% (3) 0.0247 0.6410
) 13.8% (4) <0.0001 0.0027
) None (0) 0.0006 0.4846
) 24.1% (7) 0.0001 0.0243
) 75.9% (22) 0.0001 0.0243
) 3.5% (1) <0.0001 0.0048
) None (0) 0.0012 0.4846
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nﬂammatory reaction is secondary to necrosis. MHC-I anti-
ens were overexpressed mainly in association with ﬁber
hagocytosis and regeneration.15,16 In dysferlinopathies, CD8
ymphocytes are rare and T lymphocytes invade muscle ﬁbers
nly occasionally, while both are common ﬁndings in PM.17
ysferlinopathy should be considered in the differential diag-
osis of IM that are unresponsive to steroids.
onclusion
he presence of MHC-I antigens and subtypes of T cells
xpression could be useful to help the clinician differentiate in
hose cases where differential between inﬂammatory versus
ther non-inﬂammatory myopathies cases, sometimes difﬁ-
ult to distinguish on clinical grounds. MHC-I antigens was
ore often expressed in PM;  more  cells were positive for CD4
n PM and DM;  MHC-I antigens were expressed without inﬂam-
atory cells in 14.6% of PM/DM cases; there is a high suspicion
f PM/DM (mainly PM)  when MHC-I antigens were expressed
n combination with CD4 positivity; and there is a high proba-
ility to rule out both PM and DM in the absence of both MHC-I
ntigens and CD4 expression.
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1 CD4-negative; (C) CD8-positive; (D) CD8-negative.
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